Laurent Castéra1,2, Valentin Harter3,4, Etienne Muller3,5, Sophie Krieger3,5,6, Nicolas Goardon3, Agathe Ricou3, Antoine Rousselin3, Germain Paimparay3, Angelina Legros3, Olivia Bruet3, Céline Quesnelle3, Florian Domin3, Chankannira San3, Baptiste Brault3, Robin Fouillet3, Caroline Abadie7, Odile Béra8, Pascaline Berthet9, Thierry Frébourg5,10, Dominique Vaur3,5. 1. Laboratory of Cancer Biology and Genetics, Comprehensive Cancer Center François Baclesse, Caen, France. l.castera@baclesse.fr. 2. Inserm U1245, Rouen University, Normandy Centre for Genomic and Personalized Medicine, Rouen, France. l.castera@baclesse.fr. 3. Laboratory of Cancer Biology and Genetics, Comprehensive Cancer Center François Baclesse, Caen, France. 4. Northwest Data Center (CTD-CNO), Comprehensive Cancer Center François Baclesse, Caen, France. 5. Inserm U1245, Rouen University, Normandy Centre for Genomic and Personalized Medicine, Rouen, France. 6. Université Caen-Normandie, Caen, France. 7. Department of Genetics, Comprehensive Cancer Center Eugène Marquis, Rennes, France. 8. Department of Genetics, CHU, Fort de France, France. 9. Department of Genetics, Comprehensive Cancer Center François Baclesse, Caen, France. 10. Department of Genetics, University Hospital, Rouen, France.
Abstract
PURPOSE: Integration of gene panels in the diagnosis of hereditary breast and ovarian cancer (HBOC) requires a careful evaluation of the risk associated with pathogenic or likely pathogenic variants (PVs) detected in each gene. Here we analyzed 34 genes in 5131 suspected HBOC index cases by next-generation sequencing. METHODS: Using the Exome Aggregation Consortium data sets plus 571 individuals from the French Exome Project, we simulated the probability that an individual from the Exome Aggregation Consortium carries a PV and compared it to the estimated frequency within the HBOC population. RESULTS: Odds ratio conferred by PVs within BRCA1, BRCA2, PALB2, RAD51C, RAD51D, ATM, BRIP1, CHEK2, and MSH6 were estimated at 13.22 [10.01-17.22], 8.61 [6.78-10.82], 8.22 [4.91-13.05], 4.54 [2.55-7.48], 5.23 [1.46-13.17], 3.20 [2.14-4.53], 2.49 [1.42-3.97], 1.67 [1.18-2.27], and 2.50 [1.12-4.67], respectively. PVs within RAD51C, RAD51D, and BRIP1 were associated with ovarian cancer family history (OR = 11.36 [5.78-19.59], 12.44 [2.94-33.30] and 3.82 [1.66-7.11]). PALB2 PVs were associated with bilateral breast cancer (OR = 16.17 [5.48-34.10]) and BARD1 PVs with triple-negative breast cancer (OR = 11.27 [3.37-25.01]). Burden tests performed in both patients and the French Exome Project population confirmed the association of PVs of BRCA1, BRCA2, PALB2, and RAD51C with HBOC. CONCLUSION: Our results validate the integration of PALB2, RAD51C, and RAD51D in the diagnosis of HBOC and suggest that the other genes are involved in an oligogenic determinism.
PURPOSE: Integration of gene panels in the diagnosis of hereditary breast and ovarian cancer (HBOC) requires a careful evaluation of the risk associated with pathogenic or likely pathogenic variants (PVs) detected in each gene. Here we analyzed 34 genes in 5131 suspected HBOC index cases by next-generation sequencing. METHODS: Using the Exome Aggregation Consortium data sets plus 571 individuals from the French Exome Project, we simulated the probability that an individual from the Exome Aggregation Consortium carries a PV and compared it to the estimated frequency within the HBOC population. RESULTS: Odds ratio conferred by PVs within BRCA1, BRCA2, PALB2, RAD51C, RAD51D, ATM, BRIP1, CHEK2, and MSH6 were estimated at 13.22 [10.01-17.22], 8.61 [6.78-10.82], 8.22 [4.91-13.05], 4.54 [2.55-7.48], 5.23 [1.46-13.17], 3.20 [2.14-4.53], 2.49 [1.42-3.97], 1.67 [1.18-2.27], and 2.50 [1.12-4.67], respectively. PVs within RAD51C, RAD51D, and BRIP1 were associated with ovarian cancer family history (OR = 11.36 [5.78-19.59], 12.44 [2.94-33.30] and 3.82 [1.66-7.11]). PALB2 PVs were associated with bilateral breast cancer (OR = 16.17 [5.48-34.10]) and BARD1 PVs with triple-negative breast cancer (OR = 11.27 [3.37-25.01]). Burden tests performed in both patients and the French Exome Project population confirmed the association of PVs of BRCA1, BRCA2, PALB2, and RAD51C with HBOC. CONCLUSION: Our results validate the integration of PALB2, RAD51C, and RAD51D in the diagnosis of HBOC and suggest that the other genes are involved in an oligogenic determinism.
Authors: Ayse L Mindikoglu; Mustafa M Abdulsada; Antrix Jain; Jong Min Choi; Prasun K Jalal; Sridevi Devaraj; Melissa P Mezzari; Joseph F Petrosino; Antone R Opekun; Sung Yun Jung Journal: J Proteomics Date: 2020-01-09 Impact factor: 4.044
Authors: Ying L Liu; Kelsey Breen; Amanda Catchings; Megha Ranganathan; Alicia Latham; Deborah J Goldfrank; Rachel N Grisham; Kara Long Roche; Melissa K Frey; Dennis S Chi; Nadeem Abu-Rustum; Carol Aghajanian; Kenneth Offit; Zsofia K Stadler Journal: JCO Oncol Pract Date: 2021-09-28
Authors: Jeffrey N Weitzel; John Kidd; Ryan Bernhisel; Susan Shehayeb; Paul Frankel; Kathleen R Blazer; Diana Turco; Bita Nehoray; Kim McGreevy; Kira Svirsky; Krystal Brown; Anna Gardiner; Mary Daly; Elisha Hughes; Shelly Cummings; Jennifer Saam; Thomas P Slavin Journal: Breast Cancer Res Treat Date: 2021-04-07 Impact factor: 4.624
Authors: Fabienne Lesueur; Douglas F Easton; Anne-Laure Renault; Sean V Tavtigian; Jonine L Bernstein; Zsofia Kote-Jarai; Rosalind A Eeles; Dijana Plaseska-Karanfia; Lidia Feliubadaló; Banu Arun; Natalie Herold; Beatrix Versmold; Rita Katharina Schmutzler; Tú Nguyen-Dumont; Melissa C Southey; Leila Dorling; Alison M Dunning; Paola Ghiorzo; Bruna Samia Dalmasso; Eve Cavaciuti; Dorothée Le Gal; Nicholas J Roberts; Mev Dominguez-Valentin; Matti Rookus; Alexander M R Taylor; Alisa M Goldstein; David E Goldgar; Dominique Stoppa-Lyonnet; Nadine Andrieu Journal: Fam Cancer Date: 2021-06-14 Impact factor: 2.375